Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Merck
Cantor Fitzgerald
UBS
Mallinckrodt
Healthtrust

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,295,687

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,295,687 protect, and when does it expire?

Patent 9,295,687 protects KENGREAL and is included in one NDA.

This patent has ten patent family members in ten countries.

Summary for Patent: 9,295,687
Title:Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Inventor(s): Dutta; Panna (Flemington, NJ), Rafai Far; Adel (Mount-Royal, CA), Ding; Min (Irvington, NY), Motheram; Rajeshwar (Dayton, NJ)
Assignee: THE MEDICINES COMPANY (Parsippany, NJ)
Application Number:14/796,368
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,295,687

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi Usa Inc KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cipla
Boehringer Ingelheim
Covington
Chinese Patent Office
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.